--- title: "Weekly Recap | TransMedics +5.16%, most brokers rate it buy" type: "News" locale: "en" url: "https://longbridge.com/en/news/299515624.md" description: "TransMedics gained 5.16% this week to close at $86.42, while the S&P 500 slipped 0.08%, leaving the stock about 5.24 percentage points ahead of the benchmark. Weekly amplitude was 12.21% and average daily volume ran roughly 17% above its recent median, so turnover picked up noticeably. On Monday (Sep 14) the stock dipped to an intraday low of $80.585 before rebounding to close higher. Tuesday (Sep 15) saw the weekly high near $90." datetime: "2026-09-19T07:01:55.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/299515624.md) - [en](https://longbridge.com/en/news/299515624.md) - [zh-HK](https://longbridge.com/zh-HK/news/299515624.md) generator: "portal-rs" --- # Weekly Recap | TransMedics +5.16%, most brokers rate it buy ## The Week TransMedics gained 5.16% this week to close at $86.42, while the S&P 500 slipped 0.08%, leaving the stock about 5.24 percentage points ahead of the benchmark. Weekly amplitude was 12.21% and average daily volume ran roughly 17% above its recent median, so turnover picked up noticeably. On Monday (Sep 14) the stock dipped to an intraday low of $80.585 before rebounding to close higher. Tuesday (Sep 15) saw the weekly high near $90.67, followed by three sessions of fading momentum, and Friday (Sep 18) closed at $86.42. The week traced a rally followed by a pullback. ## Key Events The company-specific thread this week centred on a management change and insider buying. On Monday, TransMedics announced the appointment of a new chief financial officer, and TD Cowen set a $120 target price the same day. On Wednesday (Sep 16), reports highlighted a 4.5% share price rise tied to insider buying activity, showing insiders adding shares in the open market. On the filings side, a material item dated Sep 15 was captured under a Form 4 filing. A Tuesday (Sep 15) macro note on diverging sector trends also mentioned the company, though the CFO appointment and insider buying were the more direct company-level developments. ## Analyst Ratings Thirteen analysts cover the stock: 6 rate it buy, 2 overweight, 4 hold, and 1 has no opinion, with no underweight or sell ratings. The consensus rating is buy, and the consensus target price is $97.30, about 12.59% above the week’s close of $86.42. The target range is wide, from $65 to $125, with the low end about 25% below spot and the high end about 45% above spot. Within the medical devices industry, TransMedics ranks 27th out of 142 companies, placing it among the stronger-rated names. ## The Week Ahead There are no company earnings on the calendar next week, but macro data is dense. Tuesday (Sep 22) brings the Richmond Fed composite index, Wednesday (Sep 23) the EIA weekly crude and Cushing inventories, and Thursday (Sep 24) initial jobless claims, the current account balance, new home sales, and EIA natural gas storage. Medical device valuations and risk appetite can be sensitive to rates and growth data, so these readings are worth tracking. ## In Short The stock rose this week while the consensus target sits about 12.59% above spot and the rating mix leans positive. But the target range from $65 to $125 shows real disagreement, and the latest session’s flow data points to net selling in small and medium lots. Valuation sits near 19.75x earnings and 5.78x book, levels common for growth names. Insider buying and the CFO appointment offer short-term support, but capital flows and macro data will shape the next move. What to watch is whether insider buying persists and how the macro readings affect sector risk appetite. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [TMDX.US](https://longbridge.com/en/quote/TMDX.US.md) ## Related News & Research - [Weekly Recap: TMDX CFO appointment and TD Cowen $120 target](https://longbridge.com/en/news/298909884.md) - [TransMedics reiterates 2026 revenue outlook of $737 million-$757 million](https://longbridge.com/en/news/298638704.md) - [BREAKINGVIEWS-Anthropic’s IPO is a crucial AI gut-check](https://longbridge.com/en/news/299933518.md) - [McDonald's Stock Price Forecast: MCD Tumbles to 2022 Low, Will It Fall Further or Rebound?](https://longbridge.com/en/news/299996327.md) - [Is Restaurant Upgrade Plan Altering The Investment Case For McDonald’s (MCD)?](https://longbridge.com/en/news/299948078.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**